Expansion of Unique, High-Value-Added Proprietary Products

「In addition, the high-frequency wire for transseptal puncture, an in-house product launched in March 2026, also got off to an extremely strong start.」

「In the fiscal year ending March 2026, the company added large-diameter sizes to FROZENIX 4Branched, which integrates FET and a vascular graft, in response to market trends, expanding the range of cases it can address.」

「In addition, XEROstar, a high-frequency wire for transseptal puncture and an in-house product launched in the fourth quarter, got off to a very strong start.」

「Frozen Elephant Trunk, a core product, performed steadily and maintained a high market share as a result of focusing on promotional initiatives including procedural training using the product.」

「For intracardiac defibrillation catheters, the company strengthened product competitiveness by adding models to its existing lineup and launching a new proprietary model. As a result, it maintained a market share of approximately 95% while limiting the impact of 2 competitors entering the market. For FET, the company minimized the loss of market share by focusing on sales of a new FET integrated with a vascular graft.」

「Under the medium-term priority of expanding into new fields, newly launched products in both the cerebrovascular and gastroenterology fields grew steadily, resulting in a significant increase in sales.」

「As a result, sales of the company’s proprietary EP/ablation products, its core business, increased by approximately 10% year on year, driving performance.」

「Frozenix is a growth driver in the cardiovascular field, and in August 2023 the company launched Frozenix Partial ET, a new addition to the lineup.」

「The ratio of proprietary products rose 5.2 percentage points year on year to 59.8%, due to higher sales of proprietary products resulting from an increase in AF cases and lower sales of purchased products following the change in the distribution channel for RF Needle.」

「In the fiscal year ended March 2023, the company released 2 models of vascular grafts with branch vessels to provide new options for the latest arch replacement procedures. It also began full-scale sales of Japan’s first product integrating an open stent graft with a branched vascular graft for arch replacement.」

「The company’s proprietary steerable sheath Leftee has continued to grow steadily since its launch in 2019, as its high operability has been well received in clinical practice, resulting in a significant year-on-year increase in sales.」

「Despite the impact of revisions to reimbursement prices, the ratio of proprietary products rose 2.6 percentage points from the same period of the previous year to 53.9%.」

「Despite the impact of revisions to reimbursement prices, the ratio of proprietary products rose 3.2 percentage points from the same period of the previous year to 54.6%.」

「In July 2021, the company launched the next-generation HeartLight X3. The product was highly rated for significantly shorter procedure times than the previous model, and sales were strong during the period.」

「Meanwhile, for the new endoscopic laser ablation catheter HeartLight X3, launched in August 2021, benefits including shorter procedure times than the previous model were well received. The product had a stronger-than-expected launch, and sales were well above the level of the same period of the previous year.」

「Meanwhile, sales of the new endoscopic laser ablation catheter HeartLight X3 began in August 2021. Its benefits, including shorter procedure times than the previous model, were well received, resulting in a stronger-than-expected launch, and sales were well above the level of the same period of the previous year.」

「In vascular grafts for treating aortic disease, the company’s proprietary J Graft series of surgical vascular grafts gained market share, while the one-of-a-kind FROZENIX open stent graft performed well as its contribution to minimally invasive and efficient treatment was recognized.」

「In the fiscal year ended March 2021, the company developed FROZENIX 4Branched, a product integrating an open stent graft with a four-branched vascular graft. By eliminating the need to suture the two products together in clinical practice, the product is expected to shorten surgery times, and the company is targeting a launch in the fiscal year ending March 2022.」

「In February 2021, the company launched ShockATα, a new-generation generator for the BeeAT intracardiac defibrillation catheter, with improved performance over the previous model.」

「In the vascular graft business, sales volume of the AFX2 Stent Graft System for abdominal use continued to increase. Sales volume of FROZENIX also increased year on year, as the product received even higher recognition amid the COVID-19 pandemic, when shorter treatment times were required.」

「In the vascular graft business, the market share of the AFX2 Stent Graft System for abdominal use increased. Demand also grew for FROZENIX, the company’s one-of-a-kind open stent graft, as it supports minimally invasive and efficient treatment amid growing demand for shorter treatment times to ease pressure on operating rooms and other facilities. Sales volume of both products increased year on year.」

「Sales volume of EP and ablation catheters generally declined year on year due to the decrease in the number of cases, including the company’s one-of-a-kind BeeAT catheter designed for its intracardiac defibrillation system.」

「During the period, the company’s proprietary products grew, mainly in EP/ablation and surgical products, as the number of cases increased. The company is also working to expand the scale of its proprietary product sales by focusing on exports and developing the gastroenterology field.」

「In the vascular graft business, sales volume increased year on year for FROZENIX, the company’s one-of-a-kind open stent graft used in open-chest surgery for thoracic aortic disease, as it has gained acceptance in clinical practice and is being actively used even in highly urgent surgeries. Sales volume also increased year on year for the company’s proprietary vascular grafts, helped by synergies from their use together with the open stent graft.」

「Meanwhile, sales volume increased for the endoscopic laser ablation catheter HeartLight, which was launched in July 2018. By combining an endoscope with a laser, the product enables precise treatment tailored to each case, and the company continues efforts to achieve further adoption in clinical practice.」

「The product is highly regarded in clinical practice because it is expected to reduce lead-related complications, and sales volume has grown rapidly since the Company began handling it.」

「Meanwhile, the HeartLight endoscopic laser ablation catheter, launched in July 2018, completed PMS (post-marketing surveillance study) in November 2018, and adoption by medical institutions is progressing.」

「Although sales volume of the radiofrequency ablation catheters traditionally handled by the Company continued to trend lower, the HeartLight endoscopic laser ablation catheter, launched in July 2018, completed its PMS (post-marketing surveillance study) in November 2018, and adoption by medical institutions is progressing.」

「Although sales volume of the radiofrequency ablation catheters previously handled by the Company declined, the HeartLight endoscopic laser ablation catheter, launched in July this year, has been steadily adopted by medical institutions.」

「Although the sales mix shifted toward purchased products due in part to the introduction of new products, the standalone gross profit margin improved year on year because sales of the Company’s highly profitable products expanded.」

「In the vascular graft business, sales volume of the AFX Stent Graft System for abdominal applications, used to treat aortic disease percutaneously with a catheter, increased substantially. In January this year, the Company began full-scale sales of the AFX2 Stent Graft System with an improved delivery system, and in March it launched the VELA extension, which can be combined with the main body to accommodate a wide range of procedures. The Company will work to further expand sales.」

「Sales volume of the KORA250 conditional-MRI-compatible pacemaker increased. The KORA250 has been highly rated for its class-leading compact size and long battery life. In addition, the VEGA MRI-compatible pacemaker lead, available in a wide range of sizes, was launched in June last year, and the expansion of eligible procedures also contributed to pacemaker sales.」

「In the vascular graft business, sales volume of the Company’s one-of-a-kind J-Graft FROZENIX Open Stent Graft increased year on year, supported by its high評価 in clinical practice.」

「In the vascular graft business, the Company’s one-of-a-kind J-Graft FROZENIX Open Stent Graft has been widely accepted in clinical practice as a product contributing to less invasive treatment of thoracic aortic disease requiring open-chest surgery. Sales volume increased year on year.」

「In intervention, the Figulla Flex II atrial septal occluder, launched in February last year, rapidly gained a high market share, while sales of crossing catheters continued to perform well.」

「In the vascular graft business, the J-Graft FROZENIX Open Stent Graft, a one-of-a-kind product of the Company and a product of its group, was highly rated in clinical practice as a product contributing to less invasive treatment of thoracic aortic aneurysms requiring open-chest surgery. Sales volume increased year on year. Accordingly, revenue from surgery-related products was ¥6,558 million, up 35.7% year on year.」

「In the vascular graft business, sales volume increased year on year as the J-Graft Open Stent Graft, a one-of-a-kind product of the Company and a product of its group, gained wider acceptance in clinical practice as a medical device contributing to less invasive treatment of thoracic aortic aneurysms requiring open-chest surgery.」

「The sales volume of the Company’s one-of-a-kind product, the J-Graft Open Stent Graft, increased year on year as it gained acceptance in clinical practice as a medical device contributing to less invasive treatment of thoracic aortic aneurysms requiring open-chest surgery.」

「It has become increasingly important not only to increase the sales share of existing products, but also to continue introducing products to the market with a high degree of novelty not found in conventional products.」